Crucell Reports First Orders For Contract Manufacturing Agreement with Wyeth Biotech
Leiden, The Netherlands, December 15, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it has received its first orders for the CMO agreement with New Jersey-headquartered Wyeth Biotech. The CMO agreement for formulation and filing of a vaccine was finalized end 2005 and will have the first business impact for Crucell in 2007. The vaccine will be supplied from Crucell's Swiss subsidiary.
This news became much more specific in this version (emphasis mine):www.outsourcing-pharma.com/Contract-M...
Wyeth kicks off CMO agreement with Crucell
By Anna Lewcock, 20-Dec-2006
Related topics: Contract Manufacturing, Drug delivery, formulation, Fill & finish, packaging
Crucell yesterday announced it had received the first orders from US-headquartered Wyeth Biotech. The order represents the first move following the finalisation of the contract manufacturing agreement between the two companies at the end of 2005.
The agreement is for the formulation and filing of a MENINGITIS vaccine, but Crucell remained tight-lipped regarding the volume of this and any further orders. The vaccine will be supplied from Crucell's Swiss subsidiary, Berna Biotech, which the company acquired earlier this year. The CMO agreement is expected to have the first business impact for Crucell in 2007.